Series guide · Pharma agency partnerships and stakeholder leadership

A Pharma Media Operating Model for Brands, Agencies, Data, and Measurement Partners

Design a pharma media operating model that maps decisions, evidence, owners, cadence, and escalation across brand, agency, data, and measurement partners.

Christian Guerrero Published 3 min read Part 1 of 10

The short answer

A pharma media program usually involves the brand team, one or more agencies, several data providers, a DSP or two, publishers, a measurement partner, and medical, legal, and regulatory reviewers. Each has part of the information needed to make good decisions. An operating model defines who decides what, based on which evidence, on what schedule, and what happens when something goes wrong.

Without one, decisions default to whoever sends the last email.

This anchor page introduces the partnerships and leadership series.

Four parts of an operating model

1. Decision map

List the recurring decisions: annual budget, partner selection, audience approval, creative rotation, optimization changes, measurement design, renewal. For each, note who decides, who must be consulted, and who needs to know. See the pharma media RACI.

2. Evidence standards

For each decision, define what evidence is required. A partner renewal might require an outcome study with a comparison group. A bid change might require only delivery data. Clear standards prevent decisions from being made on whatever data is convenient. See the measurement design guide.

3. Cadence

Match meeting rhythm to decision frequency:

Cadence Purpose
Weekly Pacing, quality, tactical optimization
Monthly Partner performance, test status, budget shifts within limits
Quarterly Investment decisions, measurement readouts, plan changes. See QBRs that change decisions.
Annually Strategy, partner roster, operating model review

4. Escalation

Define what counts as an issue, who handles it, and how fast. Brand safety incidents, data problems, and major delivery failures need clear paths. See the partner escalation framework.

Common design problems

  • Committees as owners. A decision owned by a group is often owned by no one. Name one accountable person.
  • Agency accountable for outcomes it does not control. If the brand controls creative approval timing, the agency cannot be fully accountable for creative performance.
  • Data partners outside the loop. Data and measurement partners often learn about plan changes late. Include them in the cadence.
  • Review teams as bottlenecks. Medical, legal, and regulatory review timelines should be built into the plan, not treated as surprises.

Write it down, briefly

An operating model does not need to be long. A few pages covering the decision map, evidence standards, cadence, and escalation paths is enough. Share it with every partner at onboarding. See how to write a programmatic brief for the planning document that sits alongside it.

Review it

Revisit the operating model each year and after any major partner change. Ask what decisions were slow, which escalations failed, and where evidence standards were ignored.

Practical takeaway

List your ten most important recurring media decisions. For each, write one accountable owner, the required evidence, and the meeting where it is made. Gaps in that list are where your operating model needs work.

Sources

External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.

Everything in this series

This guide is the entry point. Each article below answers one narrower decision in depth.

Agency & Leadership

A RACI for Pharma Brand, Agency, Data, and Measurement Teams

Clarify pharma media decision rights across brand, agency, activation, data, analytics, measurement, regulatory, privacy, and procurement teams.

3 min read →
Agency & Leadership

How to Write a Pharma Programmatic Brief That Partners Can Execute

A pharma programmatic brief structure with objective, audience, constraints, measurement, and approval gates, plus ambiguity checks before it goes to partners.

3 min read →
Agency & Leadership

How to Run a Pharma Media QBR That Changes Investment Decisions

Turn pharma media QBRs into decision forums with evidence, tradeoffs, forward scenarios, owners, and documented commitments.

3 min read →
Agency & Leadership

Agency Compensation and Incentives in Programmatic Media

Evaluate agency fees and incentives across commission, retainer, FTE, project, and outcome-linked models with transparency safeguards.

3 min read →
Agency & Leadership

A Partner Escalation Framework for Pharma Media

Classify pharma media incidents by severity, contain risk, preserve evidence, assign owners, communicate clearly, and verify remediation.

3 min read →
Agency & Leadership

How to Evaluate an Agency's Pharma Programmatic Capabilities

Capability tests for evaluating an agency's pharma programmatic skills using work samples and operating scenarios instead of pitch decks.

3 min read →
Agency & Leadership

In-House, Agency, or Hybrid Programmatic for Pharma?

A total-capability comparison of in-house, agency, and hybrid programmatic models for pharma, including governance, talent, continuity, and cost.

3 min read →
Agency & Leadership

How to Translate Media Results Into a Commercial Investment Case

Translate media evidence into a finance-ready investment case using causal strength, ranges, marginal economics, risks, options, and decision triggers.

3 min read →
Agency & Leadership

The First 90 Days for a Pharma Programmatic Associate Director

A 30-60-90 day operating plan for pharma programmatic leaders covering governance, portfolio diagnosis, measurement, talent, partners, and investment.

3 min read →

Working through this decision on a real plan?

I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.